摘要
Surgery is the standard therapy for pancreatic ductal adenocarcinoma(PDAC).After the dramatic decline of operative mortality over the past decades,the indications for pancreas resections have been continuously extended:currently resections of the portal/superior mesenteric vein are considered standard by many centers,and even arterial resections are under debate.Following these changes,different expert groups have defined resectability criteria containing a grey zone(“borderline resectable disease”)of tumors,which may be technically resectable with appropriate surgical expertise,but resection inherits an increased risk of an R1-resection[1].
